Dr. med. Thomas Ruhstaller
Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness
Bösch M, Knauer M, Ruhstaller T, Jochum W, Gastl G, Sopper S, Mörbe U, Novkovic M, Cheng H, Onder L, Ludewig B. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. Oncoimmunology 2018; 7:e1414129.
Jan 3, 2018Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness
Jan 3, 2018Oncoimmunology 2018; 7:e1414129
Bösch Maximilian, Knauer Michael, Ruhstaller Thomas, Jochum Wolfram, Gastl Guenther, Sopper Sieghart, Mörbe Urs, Novkovic Mario, Cheng Hung-Wei, Onder Lucas, Ludewig Burkhard
Neue zielgerichtete Therapien in der gynäkologischen Onkologie und Senologie
Greive L, Hornung R, Markus A, Ruhstaller T. Neue zielgerichtete Therapien in der gynäkologischen Onkologie und Senologie. info@gynäkologie 2017; 7 (6):14-16.
Dec 1, 2017Neue zielgerichtete Therapien in der gynäkologischen Onkologie und Senologie
Dec 1, 2017info@gynäkologie 2017; 7 (6):14-16
Greive Larissa, Hornung René, Markus Alexander, Ruhstaller Thomas
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
Nov 17, 2017Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Nov 17, 2017Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Regan M, Goldhirsch A, Coates A, Gelber R, Abdi E, Ruhstaller T, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H, Láng I, Fleming G, Francis P, Walley B, Pagani O. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT. Ann Oncol 2017; 28:2225-2232.
Sep 1, 2017Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT
Sep 1, 2017Ann Oncol 2017; 28:2225-2232
Regan M M, Goldhirsch A, Coates A S, Gelber R D, Abdi E A, Ruhstaller Thomas, Parmar V, Spazzapan S, Salim M, Pinotti G, Tondini C, Colleoni M, Gómez H L, Láng I, Fleming G F, Francis P A, Walley B A, Pagani O
Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Steffen T, Ruhstaller T, Brauchli P, Thierstein S, Schiesser M, Gloor B, Furrer M, Marti W, Huber O, Kettelhack C, Schnider A, Dietrich D, Swiss Group for Clinical Cancer Research (SAKK). Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. Ann Surg 2017; 269:83-87.
Jul 24, 2017Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer
Jul 24, 2017Ann Surg 2017; 269:83-87
Steffen Thomas, Ruhstaller Thomas, Brauchli Peter, Thierstein Sandra, Schiesser Marc, Gloor Beat, Furrer Markus, Marti Walter R, Huber Olivier, Kettelhack Christoph, Schnider Annelies, Dietrich Daniel, Swiss Group for Clinical Cancer Research (SAKK)
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Pestalozzi B, Novak U, Nussbaum C, Seifert B, Bigler M, Bize V, Vilei S, Rageth C, Aebi S, Borner M, Buser K, Tausch C, Dedes K, Rochlitz C, Zimmermann S, von Moos R, Winterhalder R, Ruhstaller T, Mueller A. Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). BMC cancer 2017; 17:265.
Apr 13, 2017Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
Apr 13, 2017BMC cancer 2017; 17:265
Pestalozzi Bernhard C, Novak Urban, Nussbaum Catrina Uhlmann, Seifert Bettina, Bigler Martin, Bize Vincent, Vilei Simona Berardi, Rageth Christoph, Aebi Stefan, Borner Markus, Buser Katharina, Tausch Christoph, Dedes Konstantin J, Rochlitz Christoph, Zimmermann Stefan, von Moos Roger, Winterhalder Ralph, Ruhstaller Thomas, Mueller Andreas
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
Dec 19, 2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Dec 19, 2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Rochlitz C, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R, Borner M, Bärtschi D, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na K. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial. BMC cancer 2016; 16:780.
Oct 10, 2016SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Oct 10, 2016BMC cancer 2016; 16:780
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Pruneri G, Regan M, Gelber R, Munzone E, Cancello G, Price K, Kammler R, Goldhirsch A, Gianni L, Ruhstaller T, Láng I, Criscitiello C, Curigliano G, Viale G, Vingiani A, Gray K, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat 2016; 158:323-31.
Jul 2, 2016Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00
Jul 2, 2016Breast Cancer Res Treat 2016; 158:323-31
Pruneri Giancarlo, Regan Meredith M, Gelber Richard D, Munzone Elisabetta, Cancello Giuseppe, Price Karen N, Kammler Roswitha, Goldhirsch Aron, Gianni Lorenzo, Ruhstaller Thomas, Láng István, Criscitiello Carmen, Curigliano Giuseppe, Viale Giuseppe, Vingiani Andrea, Gray Kathryn P, Colleoni Marco
Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes K. Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK). Breast Cancer Res Treat 2016; 158:51-7.
Jun 8, 2016Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK)
Jun 8, 2016Breast Cancer Res Treat 2016; 158:51-7
Matter-Walstra K, Ruhstaller Thomas, Klingbiel D, Schwenkglenks M, Dedes K J
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Ribi K, Torres R, Lombardi D, Puglisi F, Karlsson P, Ruhstaller T, Colleoni M, Coates A, Goldhirsch A, Price K, Gelber R, Regan M, Neven P, Perelló A, Kerbrat P, Luo W, Bernhard J, Francis P, Burstein H, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M, Parmar V, Tondini C, Fleming G. Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol 2016; 34:1601-10.
Mar 28, 2016Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
Mar 28, 2016J Clin Oncol 2016; 34:1601-10
Ribi Karin, Torres Roberto, Lombardi Davide, Puglisi Fabio, Karlsson Per, Ruhstaller Thomas, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Price Karen N, Gelber Richard D, Regan Meredith M, Neven Patrick, Perelló Antonia, Kerbrat Pierre, Luo Weixiu, Bernhard Jürg, Francis Prudence A, Burstein Harold J, Ciruelos Eva, Bellet Meritxell, Pavesi Lorenzo, Lluch Ana, Visini Marilena, Parmar Vani, Tondini Carlo, Fleming Gini F
Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
Cattin S, Fellay B, Pradervand S, Trojan A, Ruhstaller T, Rüegg C, Fürstenberger G. Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients. Oncotarget 2016; 7:11137-50.
Mar 8, 2016Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients
Mar 8, 2016Oncotarget 2016; 7:11137-50
Cattin Sarah, Fellay Benoît, Pradervand Sylvain, Trojan Andreas, Ruhstaller Thomas, Rüegg Curzio, Fürstenberger Gregor
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Bernhard J, Regan M, Pagani O, Fleming G, Francis P, Price K, Coates A, Gelber R, Goldhirsch A, Parmar V, Pavesi L, Puglisi F, Luo W, Ribi K, Colleoni M, Burstein H, Tondini C, Pinotti G, Spazzapan S, Ruhstaller T, Walley B. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol 2015; 16:848-58.
Jun 16, 2015Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
Jun 16, 2015Lancet Oncol 2015; 16:848-58
Bernhard Jürg, Regan Meredith M, Pagani Olivia, Fleming Gini F, Francis Prudence A, Price Karen N, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Parmar Vani, Pavesi Lorenzo, Puglisi Fabio, Luo Weixiu, Ribi Karin, Colleoni Marco, Burstein Harold J, Tondini Carlo, Pinotti Graziella, Spazzapan Simon, Ruhstaller Thomas, Walley Barbara A
Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland
Putora P, Stahl M, Schnider A, Mariette C, Van Lanschot J, Jäger R, van der Gaast A, Eisterer W, Budach W, Bedenne L, Ruhstaller T. Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland. Radiat Oncol 2015; 10:116.
May 21, 2015Oesophageal cancer: exploring controversies overview of experts' opinions of Austria, Germany, France, Netherlands and Switzerland
May 21, 2015Radiat Oncol 2015; 10:116
Putora Paul Martin, Stahl Michael, Schnider Annelies, Mariette Christophe, Van Lanschot J Jan B, Jäger Robert, van der Gaast Ate, Eisterer Wolfgang, Budach Wilfried, Bedenne Laurent, Ruhstaller Thomas
Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Varga Z, Cassoly E, Li Q, Öhlschlegel C, Tapia C, Lehr H, Klingbiel D, Thürlimann B, Ruhstaller T. Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PloS one 2015; 10:e0123435.
Apr 17, 2015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study
Apr 17, 2015PloS one 2015; 10:e0123435
Varga Zsuzsanna, Cassoly Estelle, Li Qiyu, Öhlschlegel Christian, Tapia Coya, Lehr Hans Anton, Klingbiel Dirk, Thürlimann Beat, Ruhstaller Thomas
Trends in survival from oesophageal cancer in Switzerland
Ruhstaller T, Voker A, Lorez M. Trends in survival from oesophageal cancer in Switzerland. Schweizer Krebsbulletin 2014; 3:227-231.
Sep 1, 2014Trends in survival from oesophageal cancer in Switzerland
Sep 1, 2014Schweizer Krebsbulletin 2014; 3:227-231
Ruhstaller Thomas, Voker Arndt, Lorez Mathias
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Pagani O, Winer E, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price K, Bernhard J, Luo W, Ribi K, Viale G, Coates A, Gelber R, Goldhirsch A, Francis P, TEXT and SOFT Investigators, Ruhstaller T, Crivellari D, Puglisi F, Regan M, Walley B, Fleming G, Colleoni M, Láng I, Gomez H, Tondini C, Burstein H, Perez E, Ciruelos E, Stearns V, Bonnefoi H, Martino S, Geyer C, Pinotti G, International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371:107-18.
Jun 1, 2014Adjuvant exemestane with ovarian suppression in premenopausal breast cancer
Jun 1, 2014N Engl J Med 2014; 371:107-18
Pagani Olivia, Winer Eric P, Rabaglio-Poretti Manuela, Maibach Rudolf, Ruepp Barbara, Giobbie-Hurder Anita, Price Karen N, Bernhard Jürg, Luo Weixiu, Ribi Karin, Viale Giuseppe, Coates Alan S, Gelber Richard D, Goldhirsch Aron, Francis Prudence A, TEXT and SOFT Investigators, Ruhstaller Thomas, Crivellari Diana, Puglisi Fabio, Regan Meredith M, Walley Barbara A, Fleming Gini F, Colleoni Marco, Láng István, Gomez Henry L, Tondini Carlo, Burstein Harold J, Perez Edith A, Ciruelos Eva, Stearns Vered, Bonnefoi Hervé R, Martino Silvana, Geyer Charles E, Pinotti Graziella, International Breast Cancer Study Group
Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Templeton A, Ruhstaller T, Thürlimann B, Zaman K, von Moos R, Rochlitz C, Winterhalder R, von Rohr L, Müller A, Winkler A, Borner M, Dietrich D, Beyeler M, Hsu Schmitz S, Sun H, Surber C, Ribi K, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast 2014; 23:244-9.
Mar 20, 2014Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
Mar 20, 2014Breast 2014; 23:244-9
Templeton Arnoud, Ruhstaller Thomas, Thürlimann Beat, Zaman Khalil, von Moos Roger, Rochlitz Christoph, Winterhalder Ralph C, von Rohr Lukas, Müller Andreas, Winkler Annette, Borner Markus, Dietrich Daniel, Beyeler Michael, Hsu Schmitz Shu-Fang, Sun Hong, Surber Christian, Ribi Karin, Swiss Group for Clinical Cancer Research (SAKK) Coordinating Center
[Combined modality treatment of oesophageal cancer]
Stahl M, Ruhstaller T. [Combined modality treatment of oesophageal cancer]. Internist (Berl) 2014; 55:7-14.
Jan 1, 2014[Combined modality treatment of oesophageal cancer]
Jan 1, 2014Internist (Berl) 2014; 55:7-14
Stahl M, Ruhstaller Thomas
Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jonat W, Bachelot T, Ruhstaller T, Kuss I, Reimann U, Robertson J. Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer. Ann Oncol 2013; 24:2543-8.
Jun 20, 2013Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
Jun 20, 2013Ann Oncol 2013; 24:2543-8
Jonat W, Bachelot T, Ruhstaller Thomas, Kuss I, Reimann U, Robertson J F R